Pitawin F
Pitawin F - Image 2
Pitawin F - Image 3
,

Pitawin F

Composition:

  • Pitavastatin Calcium equivalent to Pitavastatin 2 mg

  • Fenofibrate IP 67.5 mg
    Therapeutic Class:

  • Statin + Fibrate Combination
    Schedule: Schedule H (Prescription Only)

Pitawin F is a powerful dual lipid-modifying therapy that combines Pitavastatin, a modern and insulin-friendly statin, with Fenofibrate, a PPAR-α agonist that targets triglycerides. This combination provides comprehensive control of mixed dyslipidemia, especially in patients with high cardiovascular risk and atherogenic lipid profiles.

It is particularly effective in patients with diabetes, metabolic syndrome, or residual elevated triglycerides despite statin monotherapy.

Usage of Pitawin F

Pitawin F is indicated for:

  • Mixed dyslipidemia (elevated LDL-C + TG + low HDL)

  • Hypertriglyceridemia with or without elevated LDL

  • Type 2 diabetes or metabolic syndrome with dyslipidemia

  • Residual cardiovascular risk after statin monotherapy

  • Statin-tolerant patients requiring better TG and HDL management

Mechanism of Action

🔹 Pitavastatin (2 mg)

  • Inhibits HMG-CoA reductase → reduces hepatic cholesterol synthesis

  • Increases LDL receptor activity → lowers LDL-C

  • Uniquely improves HDL-C and insulin sensitivity

  • Neutral effect on glucose metabolism (diabetes-friendly statin)

🔹 Fenofibrate (67.5 mg)

  • Activates PPAR-α → stimulates lipoprotein lipase

  • Reduces VLDL synthesis and triglyceride levels

  • Increases HDL cholesterol

  • Improves atherogenic lipid profile (non-HDL, Apo-B, AI)

Together, they provide synergistic correction of all major lipid abnormalities:
✔ ↓ LDL-C
✔ ↓ TG
✔ ↑ HDL
✔ ↓ Apo-B, non-HDL, TC

Key Benefits

✅ Comprehensive control of atherogenic dyslipidemia
✅ Effective in diabetic dyslipidemia
✅ Pitavastatin is insulin-neutral – safe in prediabetics/diabetics
✅ Better HDL-raising vs. traditional statins
✅ Once-daily, fixed-dose convenience

Common Side Effects

  • Mild myalgia or muscle cramps

  • GI discomfort, nausea, or dyspepsia

  • Elevated liver enzymes (rare)

  • Increased creatinine (fenofibrate-related, reversible)

  • Fatigue, headache

Precautions

  • Avoid in active liver disease or severe renal impairment

  • Caution in elderly or hypothyroid patients (higher risk of myopathy)

  • Baseline and periodic LFTs and CPK recommended

  • Not for use in pregnancy or breastfeeding

  • Ensure adequate hydration to protect renal function

Drug Interactions

  • Increased risk of myopathy with other fibrates, high-dose niacin, or statins

  • May interact with anticoagulants (e.g., warfarin) – monitor INR

  • Separate from bile acid sequestrants by at least 2 hours

  • Avoid alcohol and grapefruit juice

Dosage and Administration

  • One tablet once daily, preferably in the evening after a low-fat meal

  • Regular monitoring of lipid profile, LFTs, and renal function is advised

  • Encourage lifestyle and dietary modifications for optimal benefit

Storage

  • Store below 25°C, away from heat and moisture

  • Keep out of reach of children

Patient Counseling Points

  • Inform about signs of muscle pain or weakness

  • Avoid alcohol to reduce liver strain

  • Maintain a heart-healthy diet and regular exercise

  • Report any unexplained fatigue, dark urine, or yellowing of eyes

  • Regular follow-ups for lipid and liver tests are essential

Related products

Review My Order

0

Subtotal

Taxes & shipping calculated at checkout

Checkout